Powered By
How common is it that after using treatments such as Ibrance, Kisqali and others, tumors that were initially HR+ HER2 - change and become triple negative?, My question is because I have met several people who, after treatments such as Kisqali, Ibrance, and even normal chemotherapy, develop other tumors, but these change to triple negative.
Very interesting!! Thanks for asking this question :)
Absolutely correct. Teto, you stated the info perfectly.
Job well done. Thank you.
Yes it is possible. They lose receptors to adapt and resist treatment. Then they’re more aggressive and harder to treat. Unfortunately that’s the result of many many treatments if not all.
As cancer grows and spreads, it can develop mutations that make it resistant to treatments that previously worked. This means the characteristics of breast cancer cells can change over time, potentially altering their receptor status. Triple-negative breast cancer (TNBC) is particularly challenging because the cancer cells Show Full Answer
Lots of facts above. Always learning. Your control is not giving up.
Join
Your Privacy Choices
